Since induced pluripotent stem cells (iPSCs) were first developed, in 2006, they have represented an area of immense potential in disease modeling, drug discovery, and therapeutics. In recent years, advances in biology and technology have accelerated their entry into the clinical arena, and leading researchers globally are now progressing iPSC products across a wide range of indications. Despite these recent advances, significant manufacturing and regulatory hurdles stand between promising iPSC research and their entry into the market as viable solutions for patients.
The 2025 iPSC Scientific Signature Series Event will bring together global key opinion leaders from academic research labs and clinical centers, regulatory agencies, and industry. These experts will discuss and deliberate on solutions that need to be found for the barriers that are impeding iPSC therapies’ clinical translation.
Join us for front-row access to pivotal discussions, where experts will collaboratively address the most pressing challenges in the field to advance the translation of iPSC therapeutics.